Cantor Fitzgerald Comments on Zura Bio FY2025 Earnings

Zura Bio Limited (NASDAQ:ZURA) – Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Zura Bio in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer forecasts that the company will post earnings per share of ($0.40) for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Zura Bio’s current full-year earnings is ($0.65) per share.

ZURA has been the topic of a number of other research reports. HC Wainwright reaffirmed a “neutral” rating and issued a $5.00 target price on shares of Zura Bio in a report on Tuesday, December 24th. Chardan Capital lowered their price objective on shares of Zura Bio from $14.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, November 8th. Leerink Partners started coverage on shares of Zura Bio in a research note on Monday, November 4th. They set an “outperform” rating and a $15.00 target price for the company. Finally, Leerink Partnrs upgraded shares of Zura Bio to a “strong-buy” rating in a research report on Monday, November 4th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $15.80.

Zura Bio Stock Down 3.9 %

Shares of NASDAQ:ZURA opened at $1.72 on Thursday. Zura Bio has a 52-week low of $1.67 and a 52-week high of $6.35. The stock’s 50-day moving average is $2.48 and its 200-day moving average is $3.46.

Zura Bio (NASDAQ:ZURA) last posted its earnings results on Thursday, November 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.12).

Insider Buying and Selling at Zura Bio

In other news, Director Parvinder Thiara sold 1,001,633 shares of the firm’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $2.73, for a total transaction of $2,734,458.09. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 22.10% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp grew its stake in shares of Zura Bio by 15.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 47,109 shares of the company’s stock valued at $165,000 after purchasing an additional 6,412 shares during the period. Renaissance Technologies LLC boosted its stake in Zura Bio by 51.3% in the 2nd quarter. Renaissance Technologies LLC now owns 17,400 shares of the company’s stock valued at $61,000 after buying an additional 5,900 shares in the last quarter. Armistice Capital LLC grew its position in Zura Bio by 53.2% in the second quarter. Armistice Capital LLC now owns 2,524,000 shares of the company’s stock valued at $8,834,000 after acquiring an additional 876,000 shares during the period. AQR Capital Management LLC acquired a new position in Zura Bio during the second quarter worth $43,000. Finally, Forefront Analytics LLC lifted its holdings in shares of Zura Bio by 22.1% during the second quarter. Forefront Analytics LLC now owns 41,569 shares of the company’s stock valued at $145,000 after acquiring an additional 7,531 shares during the period. Institutional investors and hedge funds own 61.14% of the company’s stock.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.